UNRV Stock Overview
Unrivaled Brands, Inc. cultivates, produces, distributes, and retails medical and adult use cannabis products in California, Oregon, and Nevada.
Unrivaled Brands Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.023|
|52 Week High||US$0.45|
|52 Week Low||US$0.021|
|1 Month Change||-59.39%|
|3 Month Change||-71.17%|
|1 Year Change||-91.33%|
|3 Year Change||-93.39%|
|5 Year Change||-99.27%|
|Change since IPO||-99.87%|
Recent News & Updates
|UNRV||US Pharmaceuticals||US Market|
Return vs Industry: UNRV underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: UNRV underperformed the US Market which returned -23.2% over the past year.
|UNRV Average Weekly Movement||15.4%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: UNRV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: UNRV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Unrivaled Brands, Inc. cultivates, produces, distributes, and retails medical and adult use cannabis products in California, Oregon, and Nevada. It also operates medical marijuana retail and adult use dispensaries, cultivation, and production facilities. The company was formerly known as Terra Tech Corp. and changed its name to Unrivaled Brands, Inc. in July 2021.
Unrivaled Brands Fundamentals Summary
|UNRV fundamental statistics|
Is UNRV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UNRV income statement (TTM)|
|Cost of Revenue||US$57.27m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.19|
|Net Profit Margin||-129.39%|
How did UNRV perform over the long term?See historical performance and comparison
Is UNRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UNRV?
Other financial metrics that can be useful for relative valuation.
|What is UNRV's n/a Ratio?|
Price to Sales Ratio vs Peers
How does UNRV's PS Ratio compare to its peers?
|UNRV PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
AYTU Aytu BioPharma
VYNE VYNE Therapeutics
CANB Can B
CURR CURE Pharmaceutical Holding
UNRV Unrivaled Brands
Price-To-Sales vs Peers: UNRV is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does UNRV's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: UNRV is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Pharmaceuticals industry average (2.9x)
Price to Sales Ratio vs Fair Ratio
What is UNRV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.2x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate UNRV's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of UNRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate UNRV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate UNRV's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Unrivaled Brands forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unrivaled Brands has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of UNRV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Unrivaled Brands's filings and announcements here.
How has Unrivaled Brands performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UNRV is currently unprofitable.
Growing Profit Margin: UNRV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UNRV is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare UNRV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UNRV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: UNRV has a negative Return on Equity (-135.08%), as it is currently unprofitable.
Discover strong past performing companies
How is Unrivaled Brands's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: UNRV's short term assets ($18.2M) do not cover its short term liabilities ($75.4M).
Long Term Liabilities: UNRV's short term assets ($18.2M) do not cover its long term liabilities ($27.6M).
Debt to Equity History and Analysis
Debt Level: UNRV's net debt to equity ratio (34.8%) is considered satisfactory.
Reducing Debt: UNRV's debt to equity ratio has increased from 1.9% to 44.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UNRV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: UNRV has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.1% each year.
Discover healthy companies
What is Unrivaled Brands's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Unrivaled Brands Dividend Yield vs Market|
|Company (Unrivaled Brands)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Unrivaled Brands)||n/a|
Notable Dividend: Unable to evaluate UNRV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UNRV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UNRV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UNRV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as UNRV has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sabas Carrillo (45 yo)
Mr. Sabas Carrillo serves as Interim Chief Executive Officer of Unrivaled Brands, Inc. since August 12 2022 He serves as Chairman and Chief Executive Officer at Adnant Concepcion Acquisition Corp. He is an...
Experienced Management: UNRV's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.3%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Unrivaled Brands, Inc.'s employee growth, exchange listings and data sources
- Name: Unrivaled Brands, Inc.
- Ticker: UNRV
- Exchange: OTCPK
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$12.844m
- Shares outstanding: 554.81m
- Website: https://www.unrivaledbrands.com
Number of Employees
- Unrivaled Brands, Inc.
- 3242 S. Halladay Street
- Suite 202
- Santa Ana
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UNRV||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Feb 2012|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.